Chen Shicheng, Yu Bo, DU Guo Tu, Huang Tian Yu, Zhang Neng, Fu Ni
Department of Urology, The Second Affiliated Hospital of Zunyi Medical University, Zunyi, 563000, P. R. China.
Department of Urology, The Affiliated Hospital of Zunyi Medical University, Zunyi, 563000, P. R. China.
Discov Oncol. 2024 Sep 11;15(1):430. doi: 10.1007/s12672-024-01330-4.
KIF18B is a key member of the kinesin-8 family, involved in regulating various physiological processes such as microtubule length, spindle assembly, and chromosome alignment. This article briefly introduces the structure and physiological functions of KIF18B, examines its role in malignant tumors, and the associated carcinogenic signaling pathways such as PI3K/AKT, Wnt/β-catenin, and mTOR pathways. Research indicates that the upregulation of KIF18B enhances tumor malignancy and resistance to radiotherapy and chemotherapy. KIF18B could become a new target for anticancer drugs, offering significant potential for the treatment of malignant tumors and reducing chemotherapy resistance.
驱动蛋白家族成员18B(KIF18B)是驱动蛋白-8家族的关键成员,参与调节多种生理过程,如微管长度、纺锤体组装和染色体排列。本文简要介绍了KIF18B的结构和生理功能,探讨了其在恶性肿瘤中的作用以及相关的致癌信号通路,如PI3K/AKT、Wnt/β-连环蛋白和mTOR通路。研究表明,KIF18B的上调增强了肿瘤的恶性程度以及对放疗和化疗的抗性。KIF18B可能成为抗癌药物的新靶点,为恶性肿瘤的治疗及降低化疗抗性提供巨大潜力。